Lundbeck acquires exclusive rights for novel insomnia drug  

2007.09.25
Danish pharmaceutical company Lundbeck has acquired the exclusive rights to Circadin, a drug for the treatment of primary insomnia, for the majority of markets in Europe
Danish pharmaceutical company Lundbeck has acquired the exclusive rights to Circadin, a drug for the treatment of primary insomnia, for the majority of markets in Europe. The agreement was entered with Neurim Pharmaceuticals Ltd., a drug discovery and development company headquartered in Tel-Aviv, Israel. Lundbeck also holds the exclusive option to evaluate commercialisation in markets outside Europe.
 
Circadin was approved by the European Commission in June, indicated as monotherapy for short-term treatment of primary insomnia characterised by poor quality of sleep in patients aged 55 or above. Lundbeck plans to launch Circadin on the first markets during 2008.
 
Executive vice president Stig Løkke Pedersen, head of commercial operations says: "Circadin has turned out to be a unique treatment for poor sleep with a new mechanism of action that differs from all other approved drugs. Circadin mimics the physiological profile of the body's own melatonin secretion and will be a valuable alternative to traditional sedative hypnotics, which all have a number of drawbacks such as dependency and drowsiness."
 
Lundbeck is an international pharmaceutical company engaged in R&D, production, marketing and sales of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company generated revenues of DKK 9.2 billion (USD 1.67 bn). Lundbeck is headquartered in Copenhagen and employs approx 5,300 people globally. The news was reported by financial daily newspaper Børsen and in a Lundbeck press release.
 
Link > Lundbeck   

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×